DIMETHYLMONOTHIOARSINIC ACID-INDUCED MALIGNANTLY TRANSFORMED CELL LINE OF HUMAN KERATINOCYTES AND USE THEREOF
20230159910 · 2023-05-25
Inventors
- Yan AN (Suzhou, CN)
- Rui YAN (Suzhou, CN)
- Jiayuan MAO (Suzhou, CN)
- Qianlei YANG (Suzhou, CN)
- Haixuan XIA (Suzhou, CN)
- Qi KONG (Suzhou, CN)
- Yuanjie WEI (Suzhou, CN)
Cpc classification
C12N2501/999
CHEMISTRY; METALLURGY
C12N15/01
CHEMISTRY; METALLURGY
International classification
C12N15/01
CHEMISTRY; METALLURGY
Abstract
The present invention relates to the technical field of model establishment, and provides a dimethylmonothioarsinic acid-induced malignantly transformed cell line of human keratinocytes and use thereof. In the present invention, human keratinocytes are persistently exposed to and incubated with dimethylmonothioarsinic acid, to construct an inorganic arsenic metabolite dimethylmonothioarsinic acid (DMMTA.sup.v)-induced malignantly transformed cell model of human keratinocytes. The malignantly transformed cell model of the present invention promotes the identification of carcinogenicity of arsenic methylated metabolites, and indicates that long-term exposure to low-dose arsenic metabolite dimethylmonothioarsinic acid (DMMTA.sup.v) causes malignant transformation of skin cells, thus providing a new cell model basis and new research idea for the study of carcinogenic mechanism of arsenic.
Claims
1. A dimethylmonothioarsinic acid-induced malignantly transformed cell line of human keratinocytes, which is deposited in China General Microbiological Culture Collection Center (CGMCC, Address: Building #3, NO.1 Beichen West Road, Chaoyang District, Beijing) under CGMCC Accession No. 21419 on Dec. 30, 2020.
2. A method for constructing a dimethylmonothioarsinic acid-induced malignantly transformed cell line of human keratinocytes according to claim 1, comprising persistently exposing and incubating human keratinocytes in a medium containing 0.5-1.0 μM dimethylmonothioarsinic acid, refreshing the medium every 20-30 h, and sub-culturing and expanding to the 30-40 th passages when the cells has a confluency reaching 75-85%, to obtain the dimethylmonothioarsinic acid-induced malignantly transformed cell line of human keratinocytes.
3. The method according to claim 2, wherein the dimethylmonothioarsinic acid is prepared by a method comprising: S1. dissolving dimethylarsonic acid and sodium sulfate in water, and slowly adding concentrated sulfuric acid into the resulting solution and mixing well by stirring for 10-24 h, wherein a molar ratio of dimethylarsonic acid, sodium sulfate and concentrated sulfuric acid is 1:1.5-2:1.5-2; S2. adding hydrochloric acid into the mixed solution obtained in S1 to perform a dehydration reaction, then extracting with chloroform after the dehydration reaction to obtain an organic phase; S3. adding a saturated salt water to the organic phase obtained in S2, to collect the subnatant; S4. adding anhydrous calcium chloride to the subnatant to collect the supernatant, heating to remove the water to obtain a solid; and S5. recrystallizing the solid obtained in S4 in hexane, and removing hexane to obtain dimethylmonothioarsinic acid.
4. The method according to claim 3, wherein the recrystallization comprises standing at 0-4° C. for 10-15 h.
5. The method according to claim 2, wherein the medium is Dulbecco's modified Eagle's medium with high glucose.
6. The method according to claim 5, wherein the Dulbecco's modified Eagle's medium with high glucose comprises 80-120 μg/ml streptomycin, 80-120 U/ml penicillin and 8-12% fetal bovine serum.
7. The method according to claim 2, wherein the method further comprises indicating the malignant transformation of cells by detecting the secretion of MMP-9, the migration ability or the soft agar colony formation ability of the cells.
8. Use of the dimethylmonothioarsinic acid-induced malignantly transformed cell line of human keratinocytes according to claim 1, as a cell model in the study of carcinogenic mechanism of dimethylmonothioarsinic acid.
9. Use of the dimethylmonothioarsinic acid-induced malignantly transformed cell line of human keratinocytes according to claim 1 in screening or evaluating drugs for the treatment of cancers caused by inorganic arsenic.
Description
BRIEF DESCRIPTION OF THE DRAWINGS
[0022]
[0023]
[0024]
[0025]
[0026]
DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENTS
[0027] The present invention will be further described below with reference to the accompanying drawings and specific examples, so that those skilled in the art can better understand and implement the present invention; however, the present invention is not limited thereto.
EXAMPLE 1
[0028] Synthesis of inorganic arsenic metabolite dimethylmonothioarsinic acid (DMMTA.sup.v): 5 g (about 35.6 mmol) of DMA.sup.v powder (molecular weight 138) and 4.5 g (about 57.0 mmol) of sodium sulfide (Na.sub.2S) powder were weighed and dissolved in 150 mL ultrapure water. Then concentrated sulfuric acid was slowly added to the resulting mixture (the final molar ratio H.sub.2SO.sub.4:Na.sub.2S: DMAV=1.6:1.6:1), and then the mixture was stirred overnight with a magnetic stirrer under an argon atmosphere. The next day, hydrochloric acid was added to the mixture so that DMMTA.sup.v suffers from dehydration reaction, then chloroform was added for extraction. Subsequently saturated salt water was added and the subnatant was collected in a beaker. anhydrous calcium chloride was added to the collected subnatant and then the supernatant was collected, and the water was removed by heating in water bath. Hexane and trace mount of DMMTA.sup.v solid were added for recrystallization. The mixture was placed overnight in a refrigerator. Next day, the mixture was taken from the refrigerator and hexane was added, finally a white solid was obtained after evaporation and drying under argon atmosphere. The obtained white solid was confirmed by high performance liquid chromatography-inductively coupled plasma mass spectrometry (HPLC-ICP-MS).
[0029] Determination of appropriate exposure dose: After the HaCaT cells were treated with various concentrations (0-2 μM) of DMMTA.sup.v for 24 h, and the cell survival was detected by the CCK-8 kit. The dose with the highest cell survival rate was used as the dose for chronic exposure, as shown in
EXAMPLE 2
[0030] Two dishes of normal HaCaT cells (cell passage 0) were prepared. One dish of cells was persistently and chronically exposed to and incubated with Dulbecco's modified Eagle's medium (DMEM) with high glucose with 1.0 μM DMMTAv (containing 100 μg/ml streptomycin, 100 U/ml penicillin and 10% fetal bovine serum), and the medium was refreshed every 24 h. When the cells were grown to a confluency reaching 80%, the cells were sub-cultured and expanded up to the 35th passage. The other dish of cells was persistently and chronically exposed to and normally incubated with Dulbecco's modified Eagle's medium (DMEM) with high glucose (containing 100 μg/ml streptomycin, 100 U/ml penicillin and 10% fetal bovine serum), and the medium was refreshed every 24 h. When the cells were grown to a confluency reaching 80%, the cells were normally sub-cultured and expanded up to the 35th passage and used as the passage control group. One monitoring point is set every 7 passages to detect the cell doubling time of the 0th, 1st, 7th, 14th, 21st, 28th, 35th passages in the exposure group and the passage control group.
EXAMPLE 3
[0031] By detecting the changes in the matrix metalloproteinase-9 (MMP-9), the cell doubling time, the cell migration ability and cell anchoring independent growth, whether the cell undergoes malignant transformation is determined.
[0032] The above-described embodiments are merely preferred embodiments for the purpose of fully illustrating the present invention, and the scope of the present invention is not limited thereto. Equivalent substitutions or modifications can be made by those skilled in the art based on the present invention, which are within the scope of the present invention as defined by the claims.